Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Psychiatry, Amsterdam Neuroscience, de Boelelaan 1117, Amsterdam, The Netherlands; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Anatomy & Neurosciences, Amsterdam Neuroscience, de Boelelaan 1117, Amsterdam, The Netherlands.
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Psychiatry, Amsterdam Neuroscience, de Boelelaan 1117, Amsterdam, The Netherlands.
J Psychosom Res. 2019 Jul;122:43-51. doi: 10.1016/j.jpsychores.2019.05.001. Epub 2019 May 13.
Psychological distress has a high impact on quality of life in patients with multiple sclerosis (MS), Parkinson's disease (PD), and Huntington's disease (HD). Studies have shown that cognitive behavioral therapy (CBT) and mindfulness-based therapies (MBTs) are successful in reducing psychological distress in patients with anxiety, depressive, and chronic somatic disorders. We aimed to investigate the effectiveness of these therapies in MS, PD, and HD patients.
We performed a comprehensive literature search in PubMed, PsycINFO, Embase and the Cochrane Central Register of Controlled Trials up to March 2018. Randomized controlled trials (RCTs) investigating a CBT or MBT and reporting psychological outcome measures were included. Two separate meta-analyses were performed; one on studies comparing psychological therapy with a treatment as usual or waitlist condition and one on studies with active treatment control conditions.
The first meta-analysis (N = 12 studies, 8 in MS and 4 in PD populations) showed a significant effect size of g = 0.51 in reducing psychological distress. The second meta-analysis (N = 7 studies, in MS populations) showed a mean effect size of g = 0.36. No RCTs were found in HD populations. The overall quality of the included studies was low and considerable heterogeneity was found. No evidence was found for publication bias.
CBT and MBTs have a small to moderate effect on reducing psychological distress in patients with PD and MS. However, more research with better methodological quality and larger study samples is warranted, especially in HD patient populations.
心理困扰对多发性硬化症(MS)、帕金森病(PD)和亨廷顿病(HD)患者的生活质量有很大影响。研究表明,认知行为疗法(CBT)和正念疗法(MBTs)在减轻焦虑、抑郁和慢性躯体障碍患者的心理困扰方面是成功的。我们旨在调查这些疗法在 MS、PD 和 HD 患者中的有效性。
我们对 PubMed、PsycINFO、Embase 和 Cochrane 中央对照试验注册库进行了全面的文献检索,检索截至 2018 年 3 月。纳入了调查 CBT 或 MBT 并报告心理结果测量的随机对照试验(RCT)。我们进行了两项单独的荟萃分析;一项是比较心理治疗与常规治疗或候补治疗的研究,另一项是与积极治疗对照条件的研究。
第一项荟萃分析(N=12 项研究,8 项在 MS 人群中,4 项在 PD 人群中)显示,减轻心理困扰的效应大小 g=0.51。第二项荟萃分析(N=7 项研究,均在 MS 人群中)显示平均效应大小 g=0.36。未在 HD 人群中发现 RCT。纳入研究的整体质量较低,存在较大的异质性。未发现发表偏倚的证据。
CBT 和 MBTs 对减轻 PD 和 MS 患者的心理困扰有小到中等的效果。然而,需要更多具有更好方法学质量和更大研究样本的研究,特别是在 HD 患者人群中。